Results 171 to 180 of about 2,291,402 (391)

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Point-of-care tests for STIs: the way forward. [PDF]

, 2017
Askew, Ian, Ballard, Ronald, Holmes, King, Kiarie, James, Mabey, David, Peeling, Rosanna W, Toskin, Igor   +6 more
core   +1 more source

Point of care testing for C-reactive protein [PDF]

, 2006
Copyright © 2006 Royal Australian College of General Practitioners Copyright to Australian Family Physician. Reproduced with permission. Permission to reproduce must be sought from the publisher, The Royal Australian College of General Practitioners ...
Melbye, H., Stocks, N.
core  

Assessment of five portable blood glucose meters, a point-of-care analyzer, and color test strips for measuring blood glucose concentration in dogs [PDF]

, 2000
Leah A. Cohn, Dudley L. McCaw, Deborah Tate, J. M. Johnson   +3 more
openalex   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Rapid, Diagnostic Test for Cardiac Ischemia [PDF]

, 2017
Current methods to detect cardiac ischemia rely on biomarkers such as troponin. Elevated levels of troponin are observed hours after the cardiac event.
Contreras, Julio, Gonzales, Jose, Nasreldeen, Abdelmagid, Physioc, Emerson, Thoresen, Evan   +4 more
core   +2 more sources

Protocol for the creation and characterization of SARS-CoV-2 variant testing panels using remnant clinical samples for diagnostic assay testing

STAR Protocols
Summary: The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Alpha variant in 2020 demonstrated the need for reanalysis of diagnostic tests to ensure detection of emerging variants.
Leda Bassit, Heather B. Bowers, Morgan Greenleaf, Courtney Sabino, Eric Lai, Grace Yu, Anne Piantadosi, Ethan Wang, William O’Sick, Kaleb McLendon, Julie A. Sullivan, Raymond F. Schinazi, Gregory L. Damhorst, Wilbur Lam, Anuradha Rao   +14 more
doaj   +1 more source

The Rise and Fall of i-STAT Point-of-Care Blood Gas Testing in an Acute Care Hospital [PDF]

, 2000
Valerie L. Ng, R Kraemer, Carol Hogan, Doug Eckman, Mark S Siobal   +4 more
openalex   +1 more source

Point-of-Care Testing/Point-of-Care Testing

LaboratoriumsMedizin, 2002
Angelika Heinschink, Mathias Müller
openaire   +2 more sources

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source